Bay Area biotech company renegade.bio today announced the opening of its new lab in Berkeley, California. The lab will expand clinical diagnostic capabilities enabling on-time, precision medicine. In addition, the lab will host research and development projects using LC-MS (liquid chromatography mass spectrometry) and NGS (next-generation sequencing) technology, while expanding current PCR (polymerase chain reaction) capabilities.
In response to the pandemic, renegade.bio developed and administered SARS-CoV-2 diagnostic assays to individuals, groups, communities, and grassroots activists in New York and the San Francisco Bay Area. Additionally, it organized COVID-19 testing programs for a multitude of organizations including the United Nations, Umoja Health, the NBA, San Francisco Giants, schools and skilled nursing facilities.
“Access to diagnostics is a problem for everyone, including biotech companies,” says renegade.bio CEO Craig Rouskey. “Many strive to create life-saving assays but struggle to bring their diagnostics to market.”
The same challenges are faced by distribution and community partners that need access to testing for patients and vulnerable communities with inadequate access to health care resources.
“Improving access to diagnostics is fundamental to effective, precision medicine and quality healthcare,” says Rouskey.
Renegade.bio addresses the challenges of accessibility by connecting diagnostics with the people who need them most. While renegade.bio continues to fight COVID-19, the company will expand its offerings of innovative diagnostics for everyone’s health.
In collaboration with other biotech partners dedicated to improving public health, renegade.bio is increasing access to diagnostics that detect disease earlier and improve health outcomes for patients. Renegade.bio can make a positive impact on healthcare by increasing access to diagnostics for disease prevention throughout an individual’s life.
"The pandemic has driven home that health is not centered solely on the individual but is rooted within communities. Cutting-edge diagnostics have the potential to detect disease earlier, improve outcomes and reduce healthcare costs," says Rouskey. “By refocusing on prevention and increasing accessibility of diagnostics to those who need them most, every person can achieve better health.”
Renegade.bio is a purpose-driven, queer-led, public benefit corporation demanding better health and healthcare for all people. With roots in activism, renegade.bio’s team focuses on improving access to diagnostics. It develops health solutions for everyone — especially historically underserved populations, such as women, queer and BIPOC communities.
For more information about the company, products and services, visit www.renegade.bio.
For further information or interview opportunities contact: firstname.lastname@example.org